In all settings (and regardless of whether delivered through facility- or community based testing), it is recommended that serological testing for HCV antibody (anti- HCV) be offered with linkage to prevention, care and treatment services to the following individuals:

• Adults and adolescents from populations most affected by HCV infection

(i.e. who are either part of a population with high HCV seroprevalence or who have a history of exposure and/or high-risk behaviours for HCV infection);

• Adults, adolescents and children with a clinical suspicion of chronic viral

hepatitis (i.e. symptoms, signs, laboratory markers). Note: Periodic re-testing using HCV NAT should be considered for those with ongoing risk of acquisition or reinfection